Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Colorado, Denver
Mayo Clinic
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
City of Hope Medical Center
AstraZeneca
Centre Francois Baclesse
M.D. Anderson Cancer Center
Alaunos Therapeutics
Tempus AI
UNC Lineberger Comprehensive Cancer Center
Virginia Commonwealth University
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Incyte Corporation
Leap Therapeutics, Inc.
Dana-Farber Cancer Institute
Eisai Inc.
Yale University
Medical College of Wisconsin
Dana-Farber Cancer Institute
Carilion Clinic
Pfizer
Stanford University
University of Surrey
Ohio State University Comprehensive Cancer Center
Wake Forest University Health Sciences
University of West Attica
Columbia University
Washington University School of Medicine
Memorial Sloan Kettering Cancer Center
UNC Lineberger Comprehensive Cancer Center
Imperial College London
Five Prime Therapeutics, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Byondis B.V.
Henry Ford Health System
University of Oklahoma
NextCure, Inc.
Duke University
University of Oklahoma
Memorial Sloan Kettering Cancer Center
Stanford University
pharmaand GmbH
Eisai Inc.
Yale University
University of Iowa
Ohio State University Comprehensive Cancer Center